Unravelling multiple ligand-activation binding sites using RASSL receptors

Trends in Pharmacological Sciences

Volumn 24, Issue 10, 2003, Pages 504-507

  Pauwels, Petrus J ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 2 (2 ETHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 2,3 DIHYDRO 3 ISOPROPYL 2 OXO 1 BENZIMIDAZOLECARBOXYLIC ACID 3ALPHA TROPANYLAMIDE; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (1 PIPERIDINYL)ETHYL ESTER; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (3,5 DIMETHYLPIPERIDINO)ETHYL ESTER; 5 CARBAMOYLTRYPTAMINE; 5 METHOXYTRYPTAMINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPINE; ADRENALIN; ALPHA 2A ADRENERGIC RECEPTOR; ATIPAMEZOLE; BRIMONIDINE; CLONIDINE; DEXEFEROXAN; G PROTEIN COUPLED RECEPTOR; IDAZOXAN; LIGAND; MEDETOMIDINE; METOCLOPRAMIDE; OPIATE PEPTIDE; OXYMETAZOLINE; RECEPTORS ACTIVATED SOLELY BY SYNTHETIC LIGAND; SEROTONIN; SEROTONIN RECEPTOR; TALIPEXOLE; TEGASEROD; UNCLASSIFIED DRUG;

BAY REGION BINDING SITE; DRUG EFFICACY; DRUG RECEPTOR BINDING; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 0141953281     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.08.007     Document Type: Short Survey

References (14)

1. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15:2001;598-611.
2. Scearce-Levie K., et al. Engineering receptors activated solely by synthetic ligands (RASSLs). Trends Pharmacol. Sci. 22:2001;414-420.
3. Coward P., et al. Controlling signaling with a specifically designed Gi-coupled receptor. Proc. Natl. Acad. Sci. U. S. A. 95:1998;352-357.
4. Claeysen S., et al. A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL). J. Biol. Chem. 278:2003;699-702.
5. Pauwels P.J., Colpaert F.C. Disparate ligand-mediated Ca2+ responses by wild-type, mutant Ser200Ala and Ser204Ala α2A-adrenoceptor: Gα15 fusion proteins: evidence for multiple ligand-activation binding sites. Br. J. Pharmacol. 130:2000;1505-1512.
6. Pauwels P.J. Diverse signalling by 5-hydroxytryptamine (5-HT) receptors. Biochem. Pharmacol. 60:2000;1743-1750.
7. Strader C.D., et al. Structural basis of β-adrenergic receptor function. FASEB J. 3:1989;1825-1832.
8. Small K.L., et al. Modification of the β2-adrenergic receptor to engineer a receptor-effector complex for gene therapy. J. Biol. Chem. 276:2001;31596-31601.
9. Salminen T., et al. Three-dimensional models of α2A-adrenergic receptor complexes provide a structural explanation for ligand binding. J. Biol. Chem. 274:1999;23405-23413.
10. Pauwels P.J., Colpaert F.C. Heterogeneous ligand-mediated Ca2+ responses at wt and mutant α2A-adrenoceptors suggest multiple ligand activation binding sites at the α2A-adrenoceptor. Neuropharmacology. 39:2000;2101-2111.
11. Hoyer D., Boddeke H.W. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol. Sci. 14:1993;270-275.
12. Strange P.G. Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol. Sci. 23:2002;89-95.
13. Joubert L., et al. A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. J. Biol. Chem. 277:2002;25502-25511.
14. Redfern C.H., et al. Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. Nat. Biotechnol. 17:1999;165-169.